- Home
- CCIX vs RGNX Comparison
CCIX vs RGNX Comparison
Compare CCIX & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$14.01
Company Overview
Basic Information| Metric | CCIX | RGNX |
|---|---|---|
| Founded | 2023 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.8M | 661.2M |
| IPO Year | 2024 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CCIX | RGNX |
|---|---|---|
| Price | $10.57 | $14.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $30.29 |
| AVG Volume (30 Days) | 124.8K | ★ 611.1K |
| Earning Date | 11-07-2013 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | N/A | ★ $161,318,000.00 |
| Revenue This Year | N/A | $132.80 |
| Revenue Next Year | N/A | $48.47 |
| P/E Ratio | $42.25 | ★ N/A |
| Revenue Growth | N/A | ★ 91.30 |
| 52 Week Low | $10.21 | $5.04 |
| 52 Week High | $11.66 | $14.24 |
Technical Indicators
Market Signals| Indicator | CCIX | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 36.92 | 64.61 |
| Support Level | $10.61 | $12.61 |
| Resistance Level | $10.64 | $13.42 |
| Average True Range (ATR) | 0.02 | 0.84 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 11.11 | 92.59 |
Price Performance
Historical Comparison CCIX
RGNX
About CCIX Churchill Capital Corp IX Ordinary Shares
Churchill Capital Corp IX is a blank check company.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.